CRISPR screens for host factors critical for infection by SARS-CoV-2 variants of concern identify GATA6 as a central modulator of ACE2
Abstract The global spread of SARS-CoV-2 led to the most challenging pandemic in this century, posing major economic and health challenges worldwide. Revealing host genes essential for infection by multiple variants of SASR-CoV-2 can provide insights into the virus pathogenesis, and facilitates the development of novel broad-spectrum host-directed therapeutics. Here, employing genome-scale CRISPR screens, we provide a comprehensive data-set of cellular factors that are exploited by WT-SARS-CoV-2 as well as two additional recently emerged variants of concerns (VOCs), Alpha and Beta. These screens identified known and novel host factors critical for SARS-CoV-2 infection, including various components belonging to the Clathrin-dependent transport pathway, ubiquitination and Heparan sulfate biogenesis. In addition, the host phosphatidylglycerol biosynthesis processes appeared to have major anti-viral functions. Comparative analysis of the different VOCs revealed the host factors KREMEN2 and SETDB1 as potential unique candidates required only to the Alpha variant, providing a possible explanation for the increased infectivity of this variant. Furthermore, the analysis identified GATA6, a zinc finger transcription factor, as an essential pro-viral gene for all variants inspected. We revealed that GATA6 directly regulates ACE2 transcription and accordingly, is critical for SARS-CoV-2 cell entry. Analysis of clinical samples collected from SARS-CoV-2 infected individuals showed an elevated level of GATA6, indicating the important role GATA6 may be playing in COVID-19 pathogenesis. Finally, pharmacological inhibition of GATA6 resulted in down-modulation of ACE2 and consequently to inhibition of the viral infectivity. Overall, we show GATA6 represents a target for the development of anti-SARS-CoV-2 therapeutic strategies and reaffirm the value of the CRISPR loss-of-function screens in providing a list of potential new targets for therapeutic interventions..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
bioRxiv.org - (2022) vom: 20. Jan. Zur Gesamtaufnahme - year:2022 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Israeli, Ma’ayan [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| doi: |
10.1101/2021.07.19.452809 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI035022914 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI035022914 | ||
| 003 | DE-627 | ||
| 005 | 20230429101125.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220120s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2021.07.19.452809 |2 doi | |
| 035 | |a (DE-627)XBI035022914 | ||
| 035 | |a (biorXiv)10.1101/2021.07.19.452809 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 570 |q DE-84 | |
| 100 | 1 | |a Israeli, Ma’ayan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CRISPR screens for host factors critical for infection by SARS-CoV-2 variants of concern identify GATA6 as a central modulator of ACE2 |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract The global spread of SARS-CoV-2 led to the most challenging pandemic in this century, posing major economic and health challenges worldwide. Revealing host genes essential for infection by multiple variants of SASR-CoV-2 can provide insights into the virus pathogenesis, and facilitates the development of novel broad-spectrum host-directed therapeutics. Here, employing genome-scale CRISPR screens, we provide a comprehensive data-set of cellular factors that are exploited by WT-SARS-CoV-2 as well as two additional recently emerged variants of concerns (VOCs), Alpha and Beta. These screens identified known and novel host factors critical for SARS-CoV-2 infection, including various components belonging to the Clathrin-dependent transport pathway, ubiquitination and Heparan sulfate biogenesis. In addition, the host phosphatidylglycerol biosynthesis processes appeared to have major anti-viral functions. Comparative analysis of the different VOCs revealed the host factors KREMEN2 and SETDB1 as potential unique candidates required only to the Alpha variant, providing a possible explanation for the increased infectivity of this variant. Furthermore, the analysis identified GATA6, a zinc finger transcription factor, as an essential pro-viral gene for all variants inspected. We revealed that GATA6 directly regulates ACE2 transcription and accordingly, is critical for SARS-CoV-2 cell entry. Analysis of clinical samples collected from SARS-CoV-2 infected individuals showed an elevated level of GATA6, indicating the important role GATA6 may be playing in COVID-19 pathogenesis. Finally, pharmacological inhibition of GATA6 resulted in down-modulation of ACE2 and consequently to inhibition of the viral infectivity. Overall, we show GATA6 represents a target for the development of anti-SARS-CoV-2 therapeutic strategies and reaffirm the value of the CRISPR loss-of-function screens in providing a list of potential new targets for therapeutic interventions. | ||
| 700 | 1 | |a Finkel, Yaara |e verfasserin |4 aut | |
| 700 | 1 | |a Yahalom-Ronen, Yfat |e verfasserin |4 aut | |
| 700 | 1 | |a Paran, Nir |e verfasserin |4 aut | |
| 700 | 1 | |a Chitlaru, Theodor |e verfasserin |4 aut | |
| 700 | 1 | |a Israeli, Ofir |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen-Gihon, Inbar |e verfasserin |4 aut | |
| 700 | 1 | |a Aftalion, Moshe |e verfasserin |4 aut | |
| 700 | 1 | |a Falach, Reut |e verfasserin |4 aut | |
| 700 | 1 | |a Elia, Uri |e verfasserin |4 aut | |
| 700 | 1 | |a Nemet, Ital |e verfasserin |4 aut | |
| 700 | 1 | |a Kliker, Limor |e verfasserin |4 aut | |
| 700 | 1 | |a Mandelboim, Michal |e verfasserin |4 aut | |
| 700 | 1 | |a Beth-Din, Adi |e verfasserin |4 aut | |
| 700 | 1 | |a Israely, Tomer |e verfasserin |4 aut | |
| 700 | 1 | |a Cohen, Ofer |e verfasserin |4 aut | |
| 700 | 1 | |a Stern-Ginossar, Noam |e verfasserin |4 aut | |
| 700 | 1 | |a Bercovich-Kinori, Adi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2022) vom: 20. Jan. |
| 773 | 1 | 8 | |g year:2022 |g day:20 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2021.07.19.452809 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 912 | |a SSG-OLC-PHA | ||
| 951 | |a AR | ||
| 952 | |j 2022 |b 20 |c 01 | ||
| 953 | |2 045F |a 570 | ||